ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Inflazome raises $46 million for NLRP3 inflammosome inhibitors

by Ryan Cross
November 23, 2018 | APPEARED IN VOLUME 96, ISSUE 47

Inflazome, a start-up developing small-molecule drugs that combat inflammation, raised $46 million in its series B financing to launch its first clinical trials in 2019. Inflazome is focused on inhibiting an increasingly popular innate immune system target called the NLRP3 inflammasome. NLRP3 is a protein complex that stimulates the release of proinflammatory cytokines in response to injured cells. Inflazome believes its NLRP3 inhibitor could be useful against inflammatory bowel disease, gout, osteoarthritis, and even neurodegenerative diseases like Alzheimer’s.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment